Zimbabwe has turned down a substantial American health deal valued at $367m (£272m) spanning five years due to Washington's insistence on confidential biological samples.
This rejection came to light following a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesperson has since stated that the US was requesting health data for research and commercial gain while refused to share the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further dialogue to secure a deal agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Background
This development follows a comparable case in Kenya, where a court blocked a related health funding agreement after legal challenges were raised about the security of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and accountability.
Based on statements, Sixteen nations in Africa have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our country would supply the basic resources for scientific discovery with no assurance that the final treatments would be available to our citizens if a future health crisis arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending frameworks already established via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This framework is designed to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how subsequent collaboration might be designed in a way that respects the independence and dignity of each country."
Health Experts Reaction
A leading public health body expressed it acknowledged the government's concerns, but urged that talks need to persist considering much of the nation's HIV programmes were funded by international support.
"If specific concerns exist, including those involving information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the complex debate between receiving much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.